CUMULATIVE INDEX Volume 18, Numbers 1-12, Pages 1-96 January 1999 — December 1999
December 1, 1999 3 minutes read
CUMULATIVE INDEX Volume 18, Numbers 1-12, Pages 1-96 January 1999—December 1999
A
abciximab, 9:67
ACE inhibitors, 8:62
acute MI, 2:12, 9:65, 12:93
adenosine, 4:28
alcohol consumption, 10:79
American College of Cardiology, 5:33, 6:41
American Heart Association, 12:89
amiodarone, 2:9, 11:83
angina, 1:1, 1:3
angiogenesis, 2:10
angiographic predictors, 6:46
angioplasty, 9:65
primary, 9:67
antiarrhythmics, 5:37
anticoagulants, 6:47
aortic debris, 6:47
arrhythmias
atrial, 9:68
ventricular, 2:12
ASD, 2:14
aspirin, 8:62
atherectomy
rotational, 3:17
atrial fibrillation, 2:9, 7:55, 8:59, 12:92
nonvalvular, 6:44
AVID, 12:95
B
BEST, 12:90
beta blockers, 1:3, 3:18
bundle branch block, 1:4
C
CABG Patch, 5:38
calcium blockers, 12:94
cardiac arrest, 10:76, 11:83
cardiac death, 10:79
cardiac surgery, 10:78
cardiomyopathy
dilated, 7:53
cardioversion, 8:59, 10:77
catheter ablation, 4:31
CHF, 7:53
cholesterol, 3:20
LDL, 8:63
CLASICS, 5:37
coenzyme Q, 7:53
coronary disease, 6:45, 8:63
coronary stenting, 7:49
coronary syndromes, 4:30
CPR
ACD, 10:76
standard, 10:76
C-reactive protein, 10:75
D
defibrillators
implantable, 5:37
defibrillator shocks
implantable, 8:60
digoxin, 9:72
diltiazem, 1:3
dofetilide, 11:86
DSE, 9:71
E
ELITE II, 12:91
endocardial mapping, 1:7
EPS, 7:55
estrogen, 10:75
echocardiography
dobutamine stress, 4:27
exercise, 7:50
transesophageal, 2:11, 7:51
F
Framingham Heart Study, 3:22
FRISC II, 5:35
H
heart failure, 2:9, 3:18
congestive, 11:86
hirudin, 4:30
HOPE study, 12:89
I
ibutilide, 8:59, 9:68
ICDs, 7:53, 9:70
immune system activation, 1:1
implantable defibrillators, 5:37
implantable defibrillator shocks, 8:60
L
LDL cholesterol, 8:63
left ventricle, 1:7
LV dilation, 2:13
M
Merit-Heart Failure, 6:41
MI, 6:46, 9:72
MR, 3:21, 4:29
MUSTT, 6:42
MVP, 8:57
myopathy, 12:94
O
obesity, 11:87
open artery hypothesis, 1:6
OPUS, 5:36
P
pericarditis
constrictive, 2:15
PET, 9:71
polyunsaturated fatty acids
marine, 10:73
protein
C-reactive, 10:75
PTCA, 12:93
pulmonary venous flow reversal, 4:29
Q
QT, 10:77
R
recurrent syncope, 12:91
renin-angiotensin access, 11:84
reperfusion, 9:65
restenosis
in-stent, 3:17, 3:19
S
SHOCK, 5:33
sotalol, 7:55, 8:60
stenting
coronary, 7:49
stroke, 3:20, 10:78
stroke prevention, 12:92
superior vena cava Doppler, 2:15
surveillance systems, 9:70
SVT, 4:28
syncope, 3:23, 7:53
T
tachycardia
ventricular, 1:4, 6:43
thrombocytopenia
heparin-induced, 10:75
thrombolysis, 9:67
thrombolytic therapy, 12:93
tilt table training, 12:91
TMLR, 4:25
TMR, 11:81
transcatheter closure, 2:14
trials
American College of Cardiology, 5:33, 6:41
American Heart Association, 12:89
AVID, 12:95
BEST, 12:90
CABG Patch, 5:38
CLASICS, 5:37
ELITE II, 12:91
FRISC II, 5:35
Merit-Heart Failure, 6:41
MUSTT, 6:42
OPUS, 5:36
SHOCK, 5:33
U
ultrasound predictors
angiographic, 3:19
intravascular, 3:19
V
ventricle
left, 1:7
vitamin E, 10:73
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content